Cefepime therapy for monomicrobial Enterobacter cloacae bacteremia: Unfavorable outcomes in patients infected by cefepime-susceptible dose-dependent isolates

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 12, 2015, Pages 7558-7563

  Lee, Nan Yao ^a,b   Lee, Ching Chi ^a,b   Li, Chia Wen ^a   Li, Ming Chi ^a   Chen, Po Lin ^a,b   Chang, Chia Ming ^a,b   Ko, Wen Chien ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; MEROPENEM; ANTIINFECTIVE AGENT; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATION; BLOODSTREAM INFECTION; CLINICAL ASSESSMENT; COMORBIDITY; CONTROLLED STUDY; CRITICAL ILLNESS; DISEASE SEVERITY; DRUG MEGADOSE; ENTEROBACTER CLOACAE; FEMALE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MORTALITY RATE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ANTIBIOTIC RESISTANCE; COMPLICATION; DIABETES MELLITUS; DRUG EFFECTS; ENTEROBACTERIACEAE INFECTIONS; GENE EXPRESSION; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; CEPHALOSPORINS; DIABETES COMPLICATIONS; DIABETES MELLITUS; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; GENE EXPRESSION; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84954537407     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01477-15     Document Type: Article

References (21)

1. Siedner MJ, Galar A, Guzman-Suarez BB, Kubiak DW, Baghdady N, Ferraro MJ, Hooper DC, O'Brien TF, Marty FM. 2014. Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia. Clin Infect Dis 58:1554-1563. http://dx.doi.org/10.1093/cid/ciu182.
2. Qureshi ZA, Paterson DL, Pakstis DL, Adams-Haduch JM, Sandkovsky G, Sordillo E, Polsky B, Peleg AY, Bhussar MK, Doi Y. 2011. Risk factors and outcome of extended-spectrum beta-lactamase-producing Enterobacter cloacae bloodstream infections. Int J Antimicrob Agents 37:26-32. http://dx.doi.org/10.1016/j.ijantimicag.2010.09.009.
3. Pitout JD. 2008. Multiresistant Enterobacteriaceae: new threat of an old problem. Expert Rev Anti Infect Ther 6:657-669. http://dx.doi.org/10.1586/14787210.6.5.657.
4. Sanders WE, Jr, Sanders CC. 1997. Enterobacter spp.: pathogens poised to flourish at the turn of the century. Clin Microbiol Rev 10:220-241.
5. Paterson DL. 2006. Resistance in gram-negative bacteria: enterobacteriaceae. Am J Med 119(6 Suppl 1):S20-S28. http://dx.doi.org/10.1016/j.amjmed.2006.03.013.
6. Choi SH, Lee JE, Park SJ, Lee SO, Jeong JY, Kim MN, Woo JH, Kim YS. 2008. Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use. Antimicrob Agents Chemother 52:995-1000. http://dx.doi.org/10.1128/AAC.01083-07.
7. Lee CC, Lee NY, Yan JJ, Lee HC, Chen PL, Chang CM, Wu CJ, Ko NY, Wang LR, Chi CH, Ko WC. 2010. Bacteremia due to extended-spectrumbeta-lactamase-producing Enterobacter cloacae: role of carbapenem therapy. Antimicrob Agents Chemother 54:3551-3556. http://dx.doi.org/10.1128/AAC.00055-10.
8. Drawz SM, Bonomo RA. 2010. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 23:160-201. http://dx.doi.org/10.1128/CMR.00037-09.
9. Tamma PD, Girdwood SC, Gopaul R, Tekle T, Roberts AA, Harris AD, Cosgrove SE, Carroll KC. 2013. The use of cefepime for treating AmpC beta-lactamase-producing Enterobacteriaceae. Clin Infect Dis 57:781-788. http://dx.doi.org/10.1093/cid/cit395.
10. Hilty M, Sendi P, Seiffert SN, Droz S, Perreten V, Hujer AM, Bonomo RA, Muhlemann K, Endimiani A. 2013. Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy? Int J Antimicrob Agents 41:236-249. http://dx.doi.org/10.1016/j.ijantimicag.2012.10.022.
11. Martinez-Martinez L, Conejo MC, Pascual A, Hernandez-Alles S, Ballesta S, Ramirez De Arellano-Ramos E, Benedi VJ, Perea EJ. 2000. Activities of imipenem and cephalosporins against clonally related strains of Escherichia coli hyperproducing chromosomal beta-lactamase and showing altered porin profiles. Antimicrob Agents Chemother 44:2534-2536. http://dx.doi.org/10.1128/AAC.44.9.2534-2536.2000.
12. Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ, Jones RN. 2013. Background and rationale for revised Clinical and Laboratory Standards Institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa. I. Cephalosporins and aztreonam. Clin Infect Dis 56:1301-1309. http://dx.doi.org/10.1093/cid/cit017.
13. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; 20th informational supplement. CLSI document M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
14. European Committee on Antimicrobial Susceptibility Testing. 2013. Breakpoint tables for interpretation of MICs and zone diameters, version 1.0. European Committee on Antimicrobial Susceptibility Testing. http://www.eucast.org. Accessed 14 June 2013.
15. Nguyen HM, Shier KL, Graber CJ. 2014. Determining a clinical framework for use of cefepime and beta-lactam/beta-lactamase inhibitors in the treatment of infections caused by extended-spectrum-beta-lactamaseproducing Enterobacteriaceae. J Antimicrob Chemother 69:871-880. http://dx.doi.org/10.1093/jac/dkt450.
16. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement, vol M100 S24. Clinical and Laboratory Standards Institute, Wayne, PA.
17. Kim Y-K, Pai H, Lee H-J, Park S-E, Choi E-H, Kim J, Kim J-H, Kim E-C. 2002. Bloodstream infections by extended-spectrum β-lactamaseproducing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 46:1481-1491. http://dx.doi.org/10.1128/AAC.46.5.1481-1491.2002.
18. McCabe W, Jackson GG. 1962. Gram-negative bacteremia. I. Etiology and ecology. Arch Intern Med 110:847-855.
19. Chow JW, Yu VL. 1999. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents 11:7-12. http://dx.doi.org/10.1016/S0924-8579(98)00060-0.
20. Alves MD, Ribeiro VB, Tessari JP, Mattiello F, De Bacco G, Luz DI, Vieira FJ, Behle TF, Pasqualotto AC, Zavascki AP. 2014. Effect of cefepime dose on mortality of patients with Gram-negative bacterial bloodstream infections: a prospective cohort study. J Antimicrob Chemother 69:1681-1687. http://dx.doi.org/10.1093/jac/dku001.
21. Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC. 2013. Cefepime therapy for monomicrobial bacteremia caused by cefepimesusceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis 56:488-495. http://dx.doi.org/10.1093/cid/cis916.